Microbiome‐immune interactions and liver disease
James H. Tabibian, Cyril Varghese, Steven P. O'Hara, Nicholas F. LaRusso – 7 May 2015 – Watch a video presentation of this article
Is the gut microbiota disturbed in chronic liver disease?
Eamonn M.M. Quigley – 7 May 2015 – Watch a video presentation of this article
Care of the patient with cirrhosis
Anitha Yadav, Hugo E. Vargas – 7 May 2015 – Watch a video presentation of this article
Direct‐acting antiviral drug approvals for treatment of chronic hepatitis C virus infection: Scientific and regulatory approaches to clinical trial designs
Poonam Mishra, Jeffrey Murray, Debra Birnkrant – 7 May 2015 – Therapeutic options for treatment of chronic hepatitis C have improved substantially since the approval of direct‐acting antiviral agents (DAAs). Several interferon (IFN)‐free or IFN‐ and ribavirin (RBV)‐free treatment regimens with shorter durations and improved efficacy and safety profiles are now available. The U.S.
Direct‐acting antiviral drug approvals for treatment of chronic hepatitis C virus infection: Scientific and regulatory approaches to clinical trial designs
Poonam Mishra, Jeffrey Murray, Debra Birnkrant – 7 May 2015 – Therapeutic options for treatment of chronic hepatitis C have improved substantially since the approval of direct‐acting antiviral agents (DAAs). Several interferon (IFN)‐free or IFN‐ and ribavirin (RBV)‐free treatment regimens with shorter durations and improved efficacy and safety profiles are now available. The U.S.
Update on MELD and organ allocation
Eric F. Martin, Christopher O'Brien – 7 May 2015 – Watch a video presentation of this article
The metabolic role of the microbiota
Wiley Barton, Fergus Shanahan, Paul D. Cotter, Orla O'Sullivan – 7 May 2015 – Watch a video presentation of this article
Direct‐acting antiviral drug approvals for treatment of chronic hepatitis C virus infection: Scientific and regulatory approaches to clinical trial designs
Poonam Mishra, Jeffrey Murray, Debra Birnkrant – 7 May 2015 – Therapeutic options for treatment of chronic hepatitis C have improved substantially since the approval of direct‐acting antiviral agents (DAAs). Several interferon (IFN)‐free or IFN‐ and ribavirin (RBV)‐free treatment regimens with shorter durations and improved efficacy and safety profiles are now available. The U.S.
Contribution of nonignorable environmental factor to impairing liver disease mortality reduction target in China
Chao Dong, Shifang Peng – 7 May 2015
CD44 and CXCL9 serum protein levels predict the risk of clinically significant allograft rejection after liver transplantation
Nathanael Raschzok, Anja Reutzel‐Selke, Rosa Bianca Schmuck, Mehmet Haluk Morgul, Ulrich Gauger, Kukuh Aji Prabowo, Laura‐Marie Tannus, Annekatrin Leder, Benjamin Struecker, Sabine Boas‐Knoop, Michael Bartels, Sven Jonas, Christian Lojewski, Gero Puhl, Daniel Seehofer, Marcus Bahra, Andreas Pascher, Johann Pratschke, Igor Maximilian Sauer – 6 May 2015 – The diagnosis of acute cellular rejection (ACR) after liver transplantation is based on histological analysis of biopsies because noninvasive biomarkers for allograft rejection are not yet established for clinical routines.